Intermediate-High Risk Localized Prostate Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

According to specific studies, patients with a history of upper urinary tract infections and those who have a low glomerular filtration rate (eGFR) have a higher incidence of UTUC. Urography, the first imaging modality currently used for UTUC screening, offers greater diagnostic accuracy, and many guidelines have only recently been updated to reflect this. Upper urinary tract cancer can be treated in one of two ways. Nephron prophylaxis, also known as conservative treatment, is the preservation of the kidney, either entirely or in part, while minimizing negative effects on kidney function. Using small tools and cameras that can reach the ureters and kidneys and focus only on the tumor, ablation is a technique for eliminating tumors without performing open surgery. Chemotherapy regimens that are frequently used in treating NHL are usually used to treat RS. Usually, the overall response rate of these systems is around 30%. Rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone make up the R-CHOP chemotherapy regimen, which is the usual first-line therapy.

Description

A significant risk of illness recurrence is found in around 15% of people with localised disease. In the past, patients had the option of undergoing surgery, radiation treatment, or androgen deprivation therapy (ADT). However, a small percentage of men with the localised disease still develop deadly recurrent prostate cancer in spite of therapy. Effective treatment approaches are essential to enhancing long-term outcomes for patients at this important stage given the possibility for cure in individuals with localised illness. The possibility to lower recurrence rates and extend survival exists in multimodal therapy approaches that include local and systemic therapies. It is possible to physically feel this type of prostate cancer or to view them on an imaging test. Cancer may have a Grade Group of 2 or 3 (Gleason score of 7) and/or a PSA level between 10 and 20 ng/ml, as well as be discovered in more than half of one side of the prostate (cT2b) or both sides of the prostate (cT2c). The intermediate-risk group was further classified into categories of good and adverse outcomes. High-risk category of prostate cancers includes those that have spread outside the prostate (cT3a), fall into Grade Groups 4 or 5, have Gleason scores of 8 to 10, or have PSA levels of more than 20.

Intermediate-High Risk Localized Prostate Cancer (Epidemiology)

Prostate cancer incidence and death vary greatly over the world, and in addition to individual risk factors, a large portion of this variation has been related to variations in asymptomatic disease screening patterns. In Western nations, more than 80% of individuals with prostate cancer are present with localised illness. Prostate cancer is the second most frequent malignancy among males globally (T1-4N0M0). For instance, the age-standardized incidence rate in a low-income region like Western Africa is only 31.9 per 100000, yet the associated mortality is significant at 18.6 per 100000. In contrast, the age-standardized incidence is substantially higher in a high-income region like North America (73.7 per 100000), but the related mortality is just 7.7 per 100000, which is rather low. High-income nations often have high detection rates for localised disease, possibly as a result of PSA testing identifying earlier disease with the associated mortality reduction from treating the lower-risk disease as well as availability to more advanced diagnostic and therapeutic options.

Intermediate-High Risk Localized Prostate Cancer -Current Market Size & Forecast Trends

The market for intermediate-high risk localized prostate cancer is expected to grow significantly, with the global prostate cancer treatment market projected to increase from USD 8.1 billion in 2024 to approximately USD 12.4 billion by 2033, reflecting a compound annual growth rate (CAGR) of 4.9% during this period. This growth is driven by the rising prevalence of prostate cancer, advancements in personalized medicine, and the introduction of new therapies aimed at improving patient outcomes. Notably, recent clinical trials, such as those involving CAN-2409, have shown promising results in enhancing disease-free survival rates without adding significant toxicity to standard treatments. The U.S. market alone presents a substantial opportunity, with an addressable market potentially worth over USD 10 billion for localized prostate cancer treatments. As awareness of prostate health increases and healthcare spending rises, the market for intermediate-high risk localized prostate cancer is well-positioned for robust expansion through 2035.

In the past, systemic monotherapy using ADT, radiation therapy, or a combination of the two was used to treat high-risk prostate cancer in men, particularly if it was clinically advanced. Inadequate disease control, morbidity, and concerns about positive surgical margins all served to discourage radical prostatectomy. Studies on men with locally advanced prostate cancer, however, have discovered that they often have excellent long-term survival results. According to research by Carver and colleagues, cancer-specific survival was 85% at 10 years and 76% at 15 years. Radical prostatectomy patients benefit from local control, with rates of local recurrence averaging around 10%, despite concerns about micrometastatic disease in high-risk patients. Important local control and debulking not only enhance the effectiveness of sequential therapy using radiation therapy or ADT aimed at controlling micrometastatic and locoregional disease, but also avoid clinical complications like hematuria and obstruction. Furthermore, radical prostatectomy enables precise staging, which can aid in the selection of patients who may gain from adjuvant treatments. Additionally, data indicate that downgrading to a lower Gleason score after radical prostatectomy for high-risk prostate cancer is not uncommon.

Report Highlights

Intermediate-High Risk Localized Prostate Cancer - Current Market Trends

Intermediate-High Risk Localized Prostate Cancer - Current & Forecasted Cases across the G8 Countries

Intermediate-High Risk Localized Prostate Cancer - Market Opportunities and Sales Potential for Agents

Intermediate-High Risk Localized Prostate Cancer - Patient-based Market Forecast to 2035

Intermediate-High Risk Localized Prostate Cancer - Untapped Business Opportunities

Intermediate-High Risk Localized Prostate Cancer - Product Positioning Vis-a-vis Competitors' Products

Intermediate-High Risk Localized Prostate Cancer - KOLs Insight